Hepatology
Signal score, how each part rates
ActionabilityPrevalenceStakesEvidence strengthNovelty
See the full rubric →Machine Learning Predicts Treatment Response and Prognostic Pathways From Whole-Blood Transcriptome in Primary Biliary Cholangitis.
Clinical takeawayNo clinical action yet: a preclinical biomarker study in PBC requiring validation before clinical use.
What it foundML model predicted OCA response (AUROC 0.93) and disease progression (AUROC 0.94) in PBC using a 105-gene panel from whole-blood transcriptomics.
ContextFirst demonstration of a blood-based transcriptomic signature for PBC prognosis and treatment response, linking pathways (FXR, stress response) to outcomes.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases, 'Primary Biliary Cholangitis: 2021 Practice Guidance', 2021
Decision at stakepredicting treatment response and disease progression in PBC
American Association for the Study of Liver Diseases, 'Primary Biliary Cholangitis: 2021 Practice Guidance', 2021 · reviewed 2026-07-21 ↗Treat with first-line ursodeoxycholic acid (UDCA) 13-15 mg/kg/d divided, and assess biochemical response at 12 months using Paris-II plus continuous risk scores (Globe, UK-PBC). Escalate to a second-line agent (obeticholic acid [contraindicated in cirrhosis with portal hypertension or prior decompensation], seladelpar, elafibranor, or a fibrate) when response is inadequate, guided by a Child-Pugh/portal-hypertension hard gate, and manage pruritus with a stepwise ladder (cholestyramine → rifampin → sertraline → naltrexone). Refer for transplant evaluation for decompensation, refractory pruritus, or rising bilirubin.
Syed H … Mason AL · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗